Please select the option that best describes you:

How would you approach dose modifications and/or frequency of lenalidomide in patients with advanced renal impairment (eGFR <30)?  

The FDA package insert suggests 2.5 mg daily in these settings, while the PrE1003 study demonstrated that a higher dose is feasible. Many oncologists might avoid lenalidomide entirely for these patients. What would you do?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Excellently stated - I could not agree more!! The ...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Very very well stated - I've only very rarely used...
Medical Oncologist at University of Chicago
Great comments all around. What do you think about...
Sign in or Register to read more